90357-06-5 Bicalutamide (CDX) AKSci J10442
 
 
Loading Please Wait...
  J10442    
Bicalutamide (CDX)
, >98% (HPLC)
 
Casodex
Cosudex
N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide




IDENTITY
CAS Number:90357-06-5
MDL Number:MFCD00869971
MF:C18H14F4N2O4S
MW:430.37
SPECIFICATIONS & PROPERTIES
Purity:>98% (HPLC)
Spectra:LCMS, HPLC
Physical Form:White crystalline powder
Melting Point:191-196°C
Long-Term Storage:Store at room temperature
UN #:Not hazmat

BIOLOGICAL INFO
Solubility:DMSO: >5mg/mL; H2O: insoluble; EtOH: 7mg/mL
Application(s):Androgen receptor (AR) antagonist
Form:Free Base

REVIEW

 Bicalutamide is a non-steroidal androgen receptor inhibitor. It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen. When Bicalutamide is combined with luteinizing hormone releasing hormone (LHRH) analog therapy, the suppression of serum testosterone induced by the LHRH analog is not affected. However, in clinical trials with Bicalutamide as a single agent for prostate cancer, rises in serum testosterone and estradiol have been noted. In a subset of patients who have been treated with Bicalutamide and an LHRH agonist, and who discontinue Bicalutamide therapy due to progressive advanced prostate cancer, a reduction in Prostate Specific Antigen (PSA) and/or clinical improvement (antiandrogen withdrawal phenomenon) may be observed.

REFERENCES
[1]Panter GH, Glennon YC, Robinson J, Hargreaves A, Murray-Smith R (2012). Effects of the anti-androgen, bicalutamide, in a reduced life-cycle study with the fathead minnow (Pimephales promelas). Aquat Toxicol. 2012 Jun 15;114-115:31-8. PMID 22406617.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of January 19, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Antiandrogens


PubChem